GlaxoSmithKline News and Research

RSS

FDA approves GSK's Tanzeum as once-weekly treatment for type 2 diabetes

GlaxoSmithKline plc today announced that the US Food and Drug Administration has approved Tanzeum (albiglutide) for injection, for subcutaneous use, as a once-weekly treatment for type 2 diabetes. Tanzeum has been approved as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus.

16 Apr 2014

Study shows 25 percent of Colorado foster kids on psychotropic drugs

The rate is 12 times greater than for other children on government insurance, a new study in Colorado finds.

15 Apr 2014

Guidance on use of Tamiflu needs to be reviewed in light of most recent evidence

Tamiflu (the antiviral drug oseltamivir) shortens symptoms of influenza by half a day, but there is no good evidence to support claims that it reduces admissions to hospital or complications of influenza.

11 Apr 2014

FDA approves Teva Pharmaceutical's Generic Lovaza Capsules

Teva Pharmaceutical Industries Ltd. announces the approval of the generic equivalent to Lovaza® (Omega-3-Acid Ethyl Esters Capsules, USP), in the United States.

9 Apr 2014

MD Anderson forms research alliance with GSK to identify new therapeutic approaches to combat cancer

The University of Texas MD Anderson Cancer Center announced today it formed a research alliance with GlaxoSmithKline (GSK), a global leader in pharmaceutical development, to strengthen its efforts in advancing therapies that train the body's immune system to combat cancer.

9 Apr 2014

Proprietary Novozymes technology used in GlaxoSmithKline’s new diabetes treatment

Novozymes Biopharma DK A/S, a subsidiary of Novozymes A/S, a world leader in bioinnovation, has announced that its albumin-based VELTIS half-life extension technology is being used by GlaxoSmithKline in the recently authorized Eperzan (albiglutide) for the treatment of type 2 diabetes in Europe.

1 Apr 2014

New -7 million centre to lead research in manufacturing advanced chemical products

A new -7 million centre at the University of Leeds will lead UK research in manufacturing advanced chemical products. The Centre for Doctoral Training (CDT) in Complex Particulate Products and Processes will fund 50 new research students in a field that has been targeted by the Government as a key growth area for the UK economy.

29 Mar 2014

Two doses of HPV-16/18 AS04-adjuvanted vaccine Cervarix non-inferior to three-doses

A recent study in the journal Human Vaccines & Immunotherapeutics, showed that two doses of the HPV-16/18 AS04-adjuvanted vaccine Cervarix (GlaxoSmithKline) are non-inferior to three-doses in the current schedule.

29 Mar 2014

Study: Just 1 in 5 eligible for premium subsidies seek coverage

Sign-up rates varied greatly by state, with more than half of the $10 billion allotted so far going to consumers in California, Florida, North Carolina, Texas and New York, according to the Kaiser Family Foundation study. Meanwhile, the Treasury Department allows battered spouses filing separate income taxes to claim subsidies. Also, Merck and GlaxoSmithKline hold off on helping Obamacare enrollees with copays.

28 Mar 2014

RuiYi declares $15M Series B financing to advance monoclonal antibodies targeting GPCR receptors

RuiYi, Inc. announced today a $15 million Series B financing by existing investors: 5AM Ventures, Versant Ventures, Apposite Capital, SR One, the independent corporate healthcare venture capital fund of GlaxoSmithKline, Merck Serono Ventures, the strategic corporate venture fund of Merck Serono, and Aravis SA.

27 Mar 2014

Jury returns verdict in favor of Mylan in breach of contract case against GSK

Mylan Inc. today announced that, after a trial in the United States District Court for the District of New Jersey, a jury returned a verdict in favor of Mylan in its breach of contract lawsuit against GlaxoSmithKline (GSK) relating to Paroxetine Hydrochloride Extended-release (ER) Tablets.

27 Mar 2014

Biodelivery Sciences collaborates with Quintiles to launch BUNAVAIL in the U.S.

BioDelivery Sciences International, Inc. announced that it has entered into an agreement with Quintiles to provide a range of services to support the anticipated launch of BUNAVAIL (buprenorphine and naloxone buccal film), BDSI's proposed maintenance treatment for opioid dependence.

27 Mar 2014

First Edition: March 27, 2014

Today's headlines include more coverage of the emerging details of the Obama administration's decision to allow some consumers to enroll in health coverage after the March 31 deadline.

27 Mar 2014

Communispace launches new business unit for health care companies

Communispace – the leading consumer collaboration agency – today announced the launch of Communispace Health, a new business unit dedicated to helping health care companies collaborate with consumers to create greater impact and develop competitive advantage in the marketplace. Communispace Vice President, Corey Schwartz, has been named Managing Director of Communispace Health.

25 Mar 2014

Body clock's could be utilized to improve current therapies to delay onset of chronic lung diseases

The body clock's natural rhythm could be utilized to improve current therapies to delay the onset of chronic lung diseases.

From The University of Manchester 18 Mar 2014

New drug is effective against superbug MRSA

"I routinely call hospitals and request their yearly antibiotic susceptibility testing data," said Washington University in St. Louis' Timothy Wencewicz. "The log might say, for example, that they've treated hundreds of patients for Acinetobacter baumanni, a bacterium brought into U.S. hospitals by soldiers wounded in the Iraq war, with 30 different antibiotics.

6 Mar 2014

Agenus reports net loss attributable to common stockholders of $5.8 million for Q4 2013

Agenus Inc., a biopharmaceutical company developing a portfolio of immuno-oncology candidates, including checkpoint modulators (CPMs), heat shock protein vaccines and adjuvants, today announced its financial results and business highlights for the fourth quarter and year ended December 31, 2013.

5 Mar 2014

University of Liège joins IMI programme to develop new antibiotics against Gram-negative pathogens

More than 30 European universities and companies, led by GlaxoSmithKline, are joining forces in a six-year programme funded by the Innovative Medicines Initiative (IMI) for the sum of EUR 85 millions with the aim of developing new antibiotics against Gram-negative pathogens.

14 Feb 2014

Drive for novel antibiotics against gram-negative bacteria

Over 30 European universities, research institutes, and companies, led by GlaxoSmithKline and Uppsala University, are joining forces in a 6 year programme supported by the Innovative Medicines Initiative (IMI) to develop novel antibiotics against Gram-negative pathogens.

13 Feb 2014

Scientists receive €85 million international drive to develop new and effective drugs

An increasing biological resistance to antibiotics treatment is to be countered by Aston University scientists who will lead a €85 million international drive to develop new and effective drugs.

12 Feb 2014

GlaxoSmithKline News and Research

FDA approves GSK's Tanzeum as once-weekly treatment for type 2 diabetes

Study shows 25 percent of Colorado foster kids on psychotropic drugs

Guidance on use of Tamiflu needs to be reviewed in light of most recent evidence

FDA approves Teva Pharmaceutical's Generic Lovaza Capsules

MD Anderson forms research alliance with GSK to identify new therapeutic approaches to combat cancer

Proprietary Novozymes technology used in GlaxoSmithKline’s new diabetes treatment

New -7 million centre to lead research in manufacturing advanced chemical products

Two doses of HPV-16/18 AS04-adjuvanted vaccine Cervarix non-inferior to three-doses

Study: Just 1 in 5 eligible for premium subsidies seek coverage

RuiYi declares $15M Series B financing to advance monoclonal antibodies targeting GPCR receptors

Jury returns verdict in favor of Mylan in breach of contract case against GSK

Biodelivery Sciences collaborates with Quintiles to launch BUNAVAIL in the U.S.

First Edition: March 27, 2014

Communispace launches new business unit for health care companies

Body clock's could be utilized to improve current therapies to delay onset of chronic lung diseases

New drug is effective against superbug MRSA

Agenus reports net loss attributable to common stockholders of $5.8 million for Q4 2013

University of Liège joins IMI programme to develop new antibiotics against Gram-negative pathogens

Drive for novel antibiotics against gram-negative bacteria

Scientists receive €85 million international drive to develop new and effective drugs

Advancing Intracellular Delivery with LumiPore®

How ELRIG Is Helping Mid-Career Scientists Navigate Leadership, Career Change and Redundancy

The role of UV-Vis in biopharma QC

Latest News